Prof. Chiang graduated from the Chinese University of Hong Kong. He has completed post-fellowship training in Princess Margaret Hospital and Johns Hopkins Hospital before joining University of Hong Kong as Clinical Assistant Professor (Clinical Oncology).

His research interest focuses on the utilization of stereotactic body radiotherapy (SBRT) combination in treating hepatocellular carcinoma (HCC). He has pioneered a novel tri-modality treatment called START-FIT, which converted around 50% of incurable HCC into a curable disease with long-term survival. This innovative discovery has been published in Lancet Gastroenterology and Hepatology, JAMA Oncology, and Liver Cancer, and adopted as one of the recommended treatment strategies in the National Treatment Guideline of HCC. His works have been recognized by numerous accolades, including Faculty Best Research Award 2023, Gold Medal Prize for Best Original Research by Young Fellows of Hong Kong Academy of Medicine 2023, Best Presentation Award of 13^th Asia-Pacific Primary Liver Cancer Expert Meeting 2023, and Special Grand Prize of the 49^th International Exhibition of Inventions of Geneva. He has collaborated with Liver Transplantation Team to successfully cure a terminal liver cancer patient by using the START-FIT followed by liver transplantation, an achievement that was named among the ‘Top Ten Hong Kong Innovation and Technology News in 2023’.

1. Hepatobiliary and pancreatic (HBP) cancer
2. Combined SBRT and immunotherapy
3. Advanced radiotherapy technique in treating HBP cancer

1. Chiang CL, Chiu KWH, Chan KSK, Lee FAS, Li JCB, Wan CWS, Dai WC, Lam TC, Chen W, Wong NSM, Cheung ALY, Lee VWY, Lau VWH, El Helali A, Man K, Kong FMS, Lo CM, Chan AC. Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial. Lancet Gastroenterol Hepatol. 2023 Feb;8(2):169-178. 

2. Chiang CL, Chan KSK, Chiu KWH, Lee FAS, Chen W, Wong NSM, Ho RLM, Lee, VWY, Kwan M, Kong FM, Chan ACY. Complete Response to Locoregional Therapy plus Immunotherapy for Hepatocellular Carcinoma. JAMA Oncol. 2024 Sep 26:e244085. doi: 10.1001/jamaoncol.2024.4085. Epub ahead of print.

3. Chiang CL, Lee FAS, Chan KSK, Lee VWY, Chiu KWH, Ho RLM, Fong JKS, Wong NSM, Yip WWL, Yeung CSY, Lau VWH, Man K, Kong FM, Chan ACY. Survival Outcome Analysis of Stereotactic Body Radiotherapy and Immunotherapy (SBRT-IO) versus SBRT-Alone in Unresectable Hepatocellular Carcinoma. Liver Cancer. 2023 Oct 1;13(3):265-276.

4. Chiang CL, Chan SK, Lee SF, Wong IO, Choi HC. Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma. JAMA Netw Open. 2021 Jan 4;4(1):e2033761.

5. Chiu KWH, Chiang CL (co-first and co-corresponding author), Chan KSK, Hui Y, Ren J, Wei X, Kwok SN, Lee VHF, Chia NH, Cheung TT, Chan SL, Chan ACY, Ng KCK, Seto WK, Khong PL, Kong FM. Dual-tracer PET/CT in the management of hepatocellular carcinoma. JHEP Rep. 2024 Apr 25;6(7):101099.

6. Chiang CL, Chan AC, Chiu KW. Combined Stereotactic Body Radiotherapy and Checkpoint Inhibitor in Unresectable Hepatocellular Carcinoma: A Synergistic Treatment Strategy. Front Oncol. 2019 Nov 12;9:1157.

7. Chiang CL, Lam TC, Li JCB, Chan KSK, El Helali A, Lee YYP, Law LHT, Zheng D, Lo AWI, Kam NW, Li WS, Cheung AKW, Chow JCH, Chan SPC, Lai JWY, Lee SWM, Kong FS, Ng WT, Kwong DLW, Lee AWM. Efficacy, safety, and correlative biomarkers of bintrafusp alfa in recurrent or metastatic nasopharyngeal cancer patients: a phase II clinical trial. Lancet Reg Health West Pac. 2023 Sep 6;40:100898

8. Chiang CL, Chan KSK, Li H, Ng WT, Chow JCH, Choi HCW, Lam KO, Lee VHF, Ngan RKC, Lee AWM, Eschrich SA, Torres-Roca JF, Wong JWH. Using the genomic adjusted radiation dose (GARD) to personalize the radiation dose in nasopharyngeal cancer. Radiother Oncol. 2024 Jul;196:110287.